Difference between revisions of "NIH royalties"
Jump to navigation
Jump to search
(No difference)
|
Revision as of 00:58, April 11, 2022
NIH royalties on its patents can enrich the bureaucracy and its officers.
Since 2017, the royalty income has been declining, which have increased the pressure at the NIH to push for patentable patents rather than inexpensive medications for treating COVID-19.[1]